These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis. Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376 [TBL] [Abstract][Full Text] [Related]
4. Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA). Chin RI; Chen K; Usmani A; Chua C; Harris PK; Binkley MS; Azad TD; Dudley JC; Chaudhuri AA Mol Diagn Ther; 2019 Jun; 23(3):311-331. PubMed ID: 30941670 [TBL] [Abstract][Full Text] [Related]
5. Circulating tumor DNA: current challenges for clinical utility. Dang DK; Park BH J Clin Invest; 2022 Jun; 132(12):. PubMed ID: 35703177 [TBL] [Abstract][Full Text] [Related]
7. Detecting liquid remnants of solid tumors treated with curative intent: Circulating tumor DNA as a biomarker of minimal residual disease (Review). Chen H; Zhou Q Oncol Rep; 2023 May; 49(5):. PubMed ID: 37052271 [TBL] [Abstract][Full Text] [Related]
8. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer. Shields MD; Chen K; Dutcher G; Patel I; Pellini B Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012272 [TBL] [Abstract][Full Text] [Related]
9. Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer. Arisi MF; Dotan E; Fernandez SV Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457259 [TBL] [Abstract][Full Text] [Related]
10. Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease. Moding EJ; Nabet BY; Alizadeh AA; Diehn M Cancer Discov; 2021 Dec; 11(12):2968-2986. PubMed ID: 34785539 [TBL] [Abstract][Full Text] [Related]
11. Circulating Tumor DNA Analysis for Detection of Minimal Residual Disease After Chemoradiotherapy for Localized Esophageal Cancer. Azad TD; Chaudhuri AA; Fang P; Qiao Y; Esfahani MS; Chabon JJ; Hamilton EG; Yang YD; Lovejoy A; Newman AM; Kurtz DM; Jin M; Schroers-Martin J; Stehr H; Liu CL; Hui AB; Patel V; Maru D; Lin SH; Alizadeh AA; Diehn M Gastroenterology; 2020 Feb; 158(3):494-505.e6. PubMed ID: 31711920 [TBL] [Abstract][Full Text] [Related]
12. Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assay. Hashimoto T; Nakamura Y; Oki E; Kobayashi S; Yuda J; Shibuki T; Bando H; Yoshino T Int J Clin Oncol; 2024 May; 29(5):495-511. PubMed ID: 38551727 [TBL] [Abstract][Full Text] [Related]
13. Detection of Minimal Residual Disease Using ctDNA in Lung Cancer: Current Evidence and Future Directions. Chae YK; Oh MS J Thorac Oncol; 2019 Jan; 14(1):16-24. PubMed ID: 30296486 [TBL] [Abstract][Full Text] [Related]
14. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. Vandekerkhove G; Struss WJ; Annala M; Kallio HML; Khalaf D; Warner EW; Herberts C; Ritch E; Beja K; Loktionova Y; Hurtado-Coll A; Fazli L; So A; Black PC; Nykter M; Tammela T; Chi KN; Gleave ME; Wyatt AW Eur Urol; 2019 Apr; 75(4):667-675. PubMed ID: 30638634 [TBL] [Abstract][Full Text] [Related]
15. Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer. Yang J; Gong Y; Lam VK; Shi Y; Guan Y; Zhang Y; Ji L; Chen Y; Zhao Y; Qian F; Chen J; Li P; Zhang F; Wang J; Zhang X; Yang L; Kopetz S; Futreal PA; Zhang J; Yi X; Xia X; Yu P Cell Death Dis; 2020 May; 11(5):346. PubMed ID: 32393783 [TBL] [Abstract][Full Text] [Related]
16. ctDNA MRD Detection and Personalized Oncogenomic Analysis in Oligometastatic Colorectal Cancer From Plasma and Urine. Pellini B; Pejovic N; Feng W; Earland N; Harris PK; Usmani A; Szymanski JJ; Qaium F; Mudd J; Petty M; Jiang Y; Singh A; Maher CA; Henke LE; Park H; Ciorba MA; Kim H; Mutch MG; Pedersen KS; Tan BR; Hawkins WG; Fields RC; Chaudhuri AA JCO Precis Oncol; 2021; 5():. PubMed ID: 34250420 [TBL] [Abstract][Full Text] [Related]
17. Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)-a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma. Flach S; Howarth K; Hackinger S; Pipinikas C; Ellis P; McLay K; Marsico G; Forshew T; Walz C; Reichel CA; Gires O; Canis M; Baumeister P Br J Cancer; 2022 May; 126(8):1186-1195. PubMed ID: 35132238 [TBL] [Abstract][Full Text] [Related]
18. Circulating Tumor DNA: An Emerging Tool in Gastrointestinal Cancers. Alese OB; Cook N; Ortega-Franco A; Ulanja MB; Tan L; Tie J Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-20. PubMed ID: 35471832 [TBL] [Abstract][Full Text] [Related]
19. Clinical utility of liquid biopsy and integrative genomic profiling in early-stage and oligometastatic cancer patients treated with radiotherapy. Cifuentes GA; Santiago A; Méndez Blanco L; Fueyo M; López Martínez E; Soria R; Martín López I; Cucarella Beltrán P; Pardo-Coto P; Rodriguez-Rubi D; Urquilla K; Durán NS; Álvarez R; Lago CG; Otero A; Diñeiro M; Capín R; Cadiñanos J; Cabanillas R Br J Cancer; 2023 Mar; 128(5):857-876. PubMed ID: 36550207 [TBL] [Abstract][Full Text] [Related]
20. Developing more sensitive genomic approaches to detect radioresponse in precision radiation oncology: From tissue DNA analysis to circulating tumor DNA. He K; Zhang S; Shao LL; Yin JC; Wu X; Shao YW; Yuan S; Yu J Cancer Lett; 2020 Mar; 472():108-118. PubMed ID: 31837443 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]